Save
esh.org
The many faces of Splenic and nodal marginal zone lymphoma
ESH eLearning, Francesco Bertoni, 4147689
Panel discussion
ESH eLearning, Faculty / Presenters, 4147688
Case-based lecture: Bispecific in 2024: how and when
ESH eLearning, Kim Linton, 4147687
Case-based lecture: Beyond CD19-directed CAR-T Cell therapy: Current results
ESH eLearning, Margot Jak, 4147686
Case-based lecture: CD19 CAR-T cell therapy for relapsed/refractory diffuse large B cell lymphoma: Patient selection and treatment approach
ESH eLearning, Kai Rejeski, 4147685
Interactive case: Patient selection for CAR-T cell therapy for diffuse large B cell lymphoma
ESH eLearning, Andrea Kuhnl, 4147684
Discussion
ESH eLearning, Faculty / Presenters, 4147683
Primary CNS lymphoma: When to use an intensive therapy approach
ESH eLearning, Anca Prica, 4147682
Optimizing treatment outcomes using biomarker-driven approaches
ESH eLearning, Sirpa Leppä, 4147681
Discussion
ESH eLearning, Faculty / Presenters, 4147680
Allogeneic stem cell transplantation is the only curative option for relapsed Mantle Cell lymphoma
ESH eLearning, Stephan Mielke, 4147678
Introduction
ESH eLearning, Martin Dreyling, 4147677
Panel discussion
ESH eLearning, Faculty / Presenters, 4147676
Case-based lecture: Cutaneous T-cell lymphoma: when to consider systemic therapy and what are the best options in first and second line
ESH eLearning, Steven Horwitz, 4147675
Case-based Lecture: Rare T-cell lymphoma
ESH eLearning, Giuseppe Gritti, 4147674
Case-based Lecture: The challenge of relapsed T cell lymphoma
ESH eLearning, Kerry Savage, 4147673
Interactive case: Follicular T helper cell lymphomas: Biology and therapy
ESH eLearning, François Lemonnier, 4147672
SATELLITE SYMPOSIUM: Redefining fitness and first-line treatment selection in chronic lymphocytic leukaemia (CLL)
ESH eLearning, Faculty / Presenters, 4147671
Panel discussion
ESH eLearning, Faculty / Presenters, 4147670
Case-based lecture: Relapsed and refractory: Novel agents including bispecifics, BTKIs and other agents
ESH eLearning, Morgane Cheminant, 4147669
Case-based lecture: Optimal treatment of older patients
ESH eLearning, Mats Jerkeman, 4147668
Case-based lecture: Optimal treatment for younger patients
ESH eLearning, Martin Dreyling, 4147667
Interactive case: Should all patients initiate treatment after diagnosis?
ESH eLearning, Sylvain Carras, 4147666
Panel discussion
ESH eLearning, Faculty / Presenters, 4147665
Case-based lecture: What is the optimal treatment for Burkitt lymphoma in adults?
ESH eLearning, Martine Chamuleau, 4147664
Case-based lecture: Approach to double hit lymphomas: Is there an optimal front-line approach?
ESH eLearning, Jeremy Abramson, 4147663
Interactive case: Treatment of mediastinal large B cell lymphoma: what is the standard
ESH eLearning, Andrew Davies, 4147662
Welcome words
ESH eLearning, Faculty / Presenters, 4147660
Conference Book (PDF)
ESH eLearning, Faculty / Presenters, 4147659
Closing Remarks
ESH eLearning, Faculty / Presenters, 4147499
Panel discussion
ESH eLearning, Faculty / Presenters, 4147498
Anti-amyloid strategies
ESH eLearning, Suzanne Lentzsch, 4147497
Targeted treatment in amyloidosis
ESH eLearning, Rajshekhar Chakraborty, 4147496
Diagnosis, imaging and response assessment in amyloidosis
ESH eLearning, Ashutosh Wechalekar, 4147495
Panel discussion
ESH eLearning, Faculty / Presenters, 4147494
CARs beyond BCMA for late relapse
ESH eLearning, Sham Mailankody, 4147493
Non BCMA-TCE for late relapse
ESH eLearning, Paula Rodríguez-Otero, 4147492
Non-Immunotherapeutic approaches for late relapse
ESH eLearning, Rakesh Popat, 4147491
Panel discussion
ESH eLearning, Faculty / Presenters, 4147490
Novel triplets will win?
ESH eLearning, Ajay Nooka, 4147489
BCMA-CAR will win?
ESH eLearning, Paula Rodríguez-Otero, 4147488
BCMA-TCE will win?
ESH eLearning, Philippe Moreau, 4147487
Panel discussion
ESH eLearning, Faculty / Presenters, 4147486
Risk of infection and the era of bispecific antibodies and CAR T cells
ESH eLearning, Noopur Raje, 4147485
MRD-driven treatment of multiple myeloma
ESH eLearning, Luciano Costa, 4147484
Targeting signalling pathways and translocations
ESH eLearning, Faculty / Presenters, 4147483
Panel discussion
ESH eLearning, Faculty / Presenters, 4147482
Indefinite treatment for frail patients?
ESH eLearning, Shaji Kumar, 4147481
Who is the frail patient?
ESH eLearning, Charlotte Pawlyn, 4147479
IME SYMPOSIUM: How to sequence BCMA-directed therapies in early relapsed/ refractory multiple myeloma
ESH eLearning, Faculty / Presenters, 4147478
Panel discussion
ESH eLearning, Faculty / Presenters, 4147477
Is there still a role for ASCT?
ESH eLearning, Mohamad Mohty, 4147476
How to treat and maintain standard-risk multiple myeloma
ESH eLearning, Hartmut Goldschmidt, 4147475
High-risk newly diagnosed multiple myeloma
ESH eLearning, Martin Kaiser, 4147474
Panel discussion
ESH eLearning, Faculty / Presenters, 4147473
Immune suppression and bone disease
ESH eLearning, Suzanne Lentzsch, 4147472
Imaging in plasma cell dyscrasias: How, when and how often?
ESH eLearning, Jens Hillengass, 4147471
Clonal evolution in multiple myeloma
ESH eLearning, Eileen Boyle, 4147470
Panel discussion
ESH eLearning, Faculty / Presenters, 4147469
Smouldering multiple myeloma: cancer or condition?
ESH eLearning, Sigrún Thorsteinsdóttir, 4147468
When to start treatment for SMM
ESH eLearning, Francesca Gay, 4147467
Can genomics tell us who to treat with SMM?
ESH eLearning, C. Ola Landgren, 4147466
Panel discussion
ESH eLearning, Faculty / Presenters, 4147465
Definition and clinical significance of MGUS-like phenotype
ESH eLearning, Bruno Paiva, 4147463
Do we need to screen for MGUS?
ESH eLearning, Sigrún Thorsteinsdóttir, 4147462
Welcome
ESH eLearning, Faculty / Presenters, 4147461
Conference Book (PDF)
ESH eLearning, Faculty / Presenters, 4147456
Closing Remarks
ESH eLearning, Jorge Cortes, 4145945
Comprehensive and sensitive genomic characterisation of diverse mutation types associated with treatment resistance for patients with CML using an RNA-based model
ESH eLearning, Naranie Shanmuganathan, 4145944
Biological significance of BCR-ABL1 clonal hematopoiesis in Ph-positive acute lymphoblastic leukemia (Ph+ ALL): relevance for treatment-free remission
ESH eLearning, Emmanuelle Clappier, 4145943
It takes a village… the Saga of the reinvention of CML
ESH eLearning, Vijayalakshmi Venkatesh, 4145942
Metabolism and drug resistance in acute myeloid leukemia
ESH eLearning, Jean-Emmanuel Sarry, 4145939
Selected Abstract: Propensity-score matching analysis comparing treatment outcomes of asciminib with ponatinib in later line treatment for chronic myeloid leukemia patients
ESH eLearning, Dennis Kim, 4145938
Selected Abstract: Sex-related differences in CML outcomes in a real-world prospective registry (GQR LMC-NMP)
ESH eLearning, Lambert Busque, 4145937
Keynote Presentation: Real-world data in CML: does it match what we know from clinical trials?
ESH eLearning, Valentin Garcia Gutiérrez, 4145935
What have we learned from treatment resistance?
ESH eLearning, Neil P. Shah, 4145932
Selected Abstract: Asciminib provides long-term, durable molecular responses and a consistent safety profile in patients with T315I-mutated CML-CP with up to approximately 6 years' exposure: final analysis from a phase 1 trial
ESH eLearning, Jorge Cortes, 4145930
Selected Abstract: Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1 in CML
ESH eLearning, Fabian Lang, 4145929
Selected Abstract: Olverembatinib (HQP1351) overcomes ponatinib and/or asciminib resistance in patients with heavily pretreated/refractory chronic myeloid leukemia (CML)
ESH eLearning, Vivian G. Oehler, 4145928
Keynote Presentation: Incorporating new drugs in current treatment algorithms
ESH eLearning, Michael Mauro, 4145927
Discussion
ESH eLearning, Faculty / Presenters, 4145926
NO - keep it in reserve for those who need it
ESH eLearning, Rüdiger Hehlmann, 4145925
YES - best option for all patients in 2024
ESH eLearning, Delphine Rea, 4145924
Introduction
ESH eLearning, Tim Hughes, 4145923
Exposing the stem cells of Chronic Myeloid Leukemia using single-cell genomics
ESH eLearning, Göran Karlsson, 4145922
SATELLITE SYMPOSIUM: New perspectives in optimising TKI selection for CML patients
ESH eLearning, Faculty / Presenters, 4145921
Selected Abstract: Alterations in the BCR::ABL1 N-lobe and SH3 domain confer in vitro and clinical resistance to asciminib
ESH eLearning, Ariel Leyte-Vidal, 4145919
Selected Abstract: Systems biology of CML: Insights into primary TKI resistance and treatment-free remission
ESH eLearning, Richard Van Etten, 4145915
Keynote Presentation: The evolution and current status of predicting outcomes in CML
ESH eLearning, Nick Cross, 4145914
Microbiome disruption in cancer immunotherapy
ESH eLearning, Jonathan Peled, 4145913
Innate NK cell memory for enhanced immunotherapy
ESH eLearning, Rizwan Romee, 4145912
Understanding monoclonal B-cell lymphocytosis: is it malignant?
ESH eLearning, Sameer Parikh, 4145909
Clinical and biologic significance of MGUS
ESH eLearning, Jakub Radocha, 4145907
The expansion and progression of clonal hematopoiesis
ESH eLearning, Linde Miles, 4145906
Clonal hematopoiesis and risk of leukemia
ESH eLearning, Liran Shlush, 4145905
Introductory overview – concepts and challenges
ESH eLearning, Ehab Atallah, 4145904
Selected Abstract: Transcriptomic analysis reveals the intricacies of Ph+ ALL: Examining gene expression patterns and deletions in relation to patient prognosis
ESH eLearning, DL White, 4145903
Selected Abstract: Identification and targeting of a novel IRF7-TBK1 inflammatory pathway in blast crisis chronic myeloid leukemia
ESH eLearning, Pavithra Shyamsunder, 4145902
Keynote Presentation: Novel approaches for blast phase CML
ESH eLearning, Steffen Koschmieder, 4145900
Gene-environment interactions during progression to blast phase MPN
ESH eLearning, Adam Mead, 4145899

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings